SSA
CTNM

Schonfeld Strategic Advisors’s Contineum Therapeutics CTNM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,673
Closed -$259K – 2762
2025
Q4 		$259K Buy
22,673
+4,177
+23% +$47.7K ﹤0.01% 1623
2025
Q3 		$217K Sell
18,496
-145,628
-89% -$1.17M ﹤0.01% 1923
2025
Q2 		$652K Buy
164,124
+21,924
+15% +$95.3K ﹤0.01% 1457
2025
Q1 		$993K Buy
142,200
+16,205
+13% +$147K 0.01% 1299
2024
Q4 		$1.85M Buy
+125,995
New +$2M 0.01% 870

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Schonfeld Strategic Advisors's CTNM Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 22,673 shares — an estimated $259K sold.

Schonfeld Strategic Advisors first reported a position in CTNM in Q4 2024 and held it in 5 quarters. The position peaked at $1.85M in Q4 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 22,673 Contineum Therapeutics shares in Q1 2026, an estimated $259K.
  • Schonfeld Strategic Advisors first reported a position in Contineum Therapeutics in Q4 2024 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Contineum Therapeutics position peaked at $1.85M in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.